Abstract:Breast cancer is one of the major impediments affecting women globally. The ATP-dependant heat shock protein 90 (Hsp90) forms the central component of molecular chaperone machinery that predominantly governs the folding of newly synthesized peptides and their conformational maturation. It regulates the stability and function of numerous client proteins that are frequently upregulated and/or mutated in cancer cells, therefore, making Hsp90 inhibition a promising therapeutic strategy for the development of new efficacious drugs to treat breast cancer. In the present in silico investigation, a structure-based pharmacophore model was generated with hydrogen bond donor, hydrogen bond acceptor and hydrophobic features complementary to crucial residues Ala55, Lys58, Asp93, Ile96, Met98 and Thr184 directed at inhibiting the ATP-binding activity of Hsp90. Subsequently, the phytochemical dataset of 3210 natural compounds was screened to retrieve the prospective inhibitors after rigorous validation of the model pharmacophore. The retrieved 135 phytocompounds were further filtered by drug-likeness parameters including Lipinski's rule of five and ADMET properties, then investigated via molecular docking-based scoring. Molecular interactions were assessed using Genetic Optimisation for Ligand Docking program for 95 drug-like natural compounds against Hsp90 along with two clinical drugs as reference compounds - Geldanamycin and Radicicol. Docking studies revealed three phytochemicals are better than the investigated clinical drugs. The reference and hit compounds with dock scores of 48.27 (Geldanamycin), 40.90 (Radicicol), 73.04 (Hit1), 72.92 (Hit2) and 68.12 (Hit3) were further validated for their binding stability through molecular dynamics simulations. We propose that the non-macrocyclic scaffolds of three identified phytochemicals might aid in the development of novel therapeutic candidates against Hsp90-driven cancers.

Molecular design of anticancer drugs from marine fungi derivatives

Marine-Derived Compounds as Potential Inhibitors of Hsp90 for Anticancer and Antimicrobial Drug Development: A Comprehensive In Silico Study

Cytotoxic Compounds from Marine Fungi: Sources, Structures, and Bioactivity

An Overview of the Mechanisms of Marine Fungi-Derived Anti-Inflammatory and Anti-Tumor Agents and Their Novel Role in Drug Targeting

Molecular Targets of Active Anticancer Compounds Derived from Marine Sources

Natural bioactive compounds from marine fungi (2017–2020)

Design and Synthesis of Anti-Cancer Chimera Molecules Based on Marine Natural Products

Development of Marine-Derived Compounds for Cancer Therapy

Anticancer Effect And Structure-Activity Analysis Of Marine Products Isolated From Metabolites Of Mangrove Fungi In The South China Sea

Discovery of Novel Tubulin Polymerization Inhibitors by Utilizing 3D-QSAR, Molecular Docking and Molecular Dynamics Simulation

Molecular Docking, Design, Synthesis and Antifungal Activity Study of Novel Triazole Derivatives

Marine Natural Products: A Potential Source Of Anti-Hepatocellular Carcinoma Drugs

Secondary metabolites from the deep-sea derived fungus Aspergillus terreus MCCC M28183

Natural compounds as potential Hsp90 inhibitors for breast cancer-Pharmacophore guided molecular modelling studies

Phenyl Ethers from the Marine-Derived Fungus Aspergillus tabacinus and Their Antimicrobial Activity Against Plant Pathogenic Fungi and Bacteria

Microtubule-targeting Anticancer Agents from Marine Natural Substance.

Design, Synthesis and Antitumor Activity Evaluation of Chrysamide B Derivatives

Optimization of substituted cinnamic acyl sulfonamide derivatives as tubulin polymerization inhibitors with anticancer activity.

Potential of Anti-Cancer Activity of Secondary Metabolic Products from Marine Fungi

Synthesis, Biological Evaluation, and Molecular Docking Studies of 1,3,4-Thiadiazol-2-amide Derivatives As Novel Anticancer Agents

Antitubercular Metabolites from the Marine-Derived Fungus Strain Aspergillus Fumigatus MF029.